Spots Global Cancer Trial Database for stage iv skin melanoma

Every month we try and update this database with for stage iv skin melanoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery	NCT00110019	Mucosal Melanom... Recurrent Melan... Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M...	Carboplatin Laboratory Biom... Paclitaxel Pharmacological... Placebo Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma	NCT01961115	Mucosal Melanom... Recurrent Melan... Recurrent Uveal... Stage IIIA Skin... Stage IIIA Uvea... Stage IIIB Skin... Stage IIIB Uvea... Stage IIIC Skin... Stage IIIC Uvea... Stage IV Skin M... Stage IV Uveal ...	Epacadostat MELITAC 12.1 Pe...	18 Years -	Fred Hutchinson Cancer Center
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma	NCT00387751	Recurrent Melan... Stage III Skin ... Stage IV Skin M...	Bevacizumab Laboratory Biom... Pharmacological... Sorafenib Tosyl...	18 Years - 120 Years	National Cancer Institute (NCI)
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases	NCT02858869	Metastatic Mali... Metastatic Mela... Mucosal Melanom... Ocular Melanoma Stage IV Non-Sm... Stage IV Skin M... Melanoma of Unk...	Pembrolizumab Stereotactic Ra...	18 Years -	Emory University
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors	NCT02650635	Colorectal Aden... Metastatic Panc... Recurrent Breas... Recurrent Color... Recurrent Melan... Recurrent Non-S... Recurrent Pancr... Recurrent Renal... Solid Neoplasm Stage IV Breast... Stage IV Non-Sm... Stage IV Renal ... Stage IV Skin M... Stage IVA Color... Stage IVA Pancr... Stage IVB Color... Stage IVB Pancr...	Cyclophosphamid... Laboratory Biom... Pegfilgrastim Pharmacological... TLR8 Agonist VT...	18 Years -	Mayo Clinic
Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma	NCT01744171	Recurrent Melan... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M...	Recombinant Hum... Laboratory Biom...	18 Years -	Roswell Park Cancer Institute
Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma	NCT01970527	Recurrent Melan... Stage IV Skin M...	Ipilimumab Laboratory Biom... Pharmacological... Stereotactic Bo...	18 Years -	University of Washington
Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma	NCT01307618	Recurrent Melan... Stage IV Skin M...	NA17.A2 Peptide... Recombinant MAG... Recombinant Int... MART-1 Antigen Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma	NCT01460875	Stage IA Skin M... Stage IB Skin M... Stage IIA Skin ... Stage IIB Skin ... Stage IIC Skin ... Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M...	recombinant int... laboratory biom...	12 Years -	Ohio State University Comprehensive Cancer Center
SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine	NCT02716948	Metastatic Mali... Metastatic Mali... Stage IV Skin M...	Laboratory Biom... Nivolumab Stereotactic Ra...	18 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma	NCT00866177	Recurrent Melan... Stage III Skin ... Stage IV Skin M...	Laboratory Biom... Selumetinib	18 Years -	National Cancer Institute (NCI)
Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy	NCT02680184	Melanoma	CMP-001 Pembrolizumab	18 Years -	Regeneron Pharmaceuticals
Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma	NCT01960634	Stage IV Skin M...		-	Grupo Español Multidisciplinar de Melanoma
Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification	NCT02812693	Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M...	Imatinib Mesyla... Laboratory Biom... Pembrolizumab	18 Years -	Ohio State University Comprehensive Cancer Center
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery	NCT01989559	Recurrent Melan... Stage IA Skin M... Stage IB Skin M... Stage IIA Skin ... Stage IIB Skin ... Stage IIC Skin ... Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M...	gp100:209-217(2... HPV 16 E7:12-20... Laboratory Biom...	-	National Cancer Institute (NCI)
Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma	NCT00397982	Recurrent Melan... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M...	Bevacizumab Laboratory Biom... Temsirolimus Therapeutic Con...	18 Years -	National Cancer Institute (NCI)
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors	NCT02650635	Colorectal Aden... Metastatic Panc... Recurrent Breas... Recurrent Color... Recurrent Melan... Recurrent Non-S... Recurrent Pancr... Recurrent Renal... Solid Neoplasm Stage IV Breast... Stage IV Non-Sm... Stage IV Renal ... Stage IV Skin M... Stage IVA Color... Stage IVA Pancr... Stage IVB Color... Stage IVB Pancr...	Cyclophosphamid... Laboratory Biom... Pegfilgrastim Pharmacological... TLR8 Agonist VT...	18 Years -	Mayo Clinic
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery	NCT01989559	Recurrent Melan... Stage IA Skin M... Stage IB Skin M... Stage IIA Skin ... Stage IIB Skin ... Stage IIC Skin ... Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M...	gp100:209-217(2... HPV 16 E7:12-20... Laboratory Biom...	-	National Cancer Institute (NCI)
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy	NCT03719131	Cutaneous Melan... Cutaneous Melan... Stage III Melan... Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M... Unresectable Me...	Nivolumab Rituximab and H... Ipilimumab	18 Years -	Emory University
Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification	NCT02812693	Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M...	Imatinib Mesyla... Laboratory Biom... Pembrolizumab	18 Years -	Ohio State University Comprehensive Cancer Center
A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases	NCT02941744	Stage IIIC Skin... Stage IV Skin M...	nivolumab ipilimumab	18 Years -	Universitair Ziekenhuis Brussel
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery	NCT00110019	Mucosal Melanom... Recurrent Melan... Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M...	Carboplatin Laboratory Biom... Paclitaxel Pharmacological... Placebo Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors	NCT01131234	Adult Anaplasti... Adult Anaplasti... Adult Anaplasti... Adult Brain Ste... Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Mixed Gli... Adult Solid Neo... Male Breast Car... Recurrent Adult... Recurrent Breas... Recurrent Colon... Recurrent Melan... Recurrent Non-S... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Recurrent Renal... Stage III Pancr... Stage III Renal... Stage IIIA Colo... Stage IIIA Non-... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Rect... Stage IIIA Skin... Stage IIIB Brea... Stage IIIB Colo... Stage IIIB Non-... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Rect... Stage IIIB Skin... Stage IIIC Brea... Stage IIIC Colo... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Rect... Stage IIIC Skin... Stage IV Breast... Stage IV Non-Sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Renal ... Stage IV Skin M... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta...	Gamma-Secretase... Cediranib Malea... Pharmacological... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma	NCT03229278	Lymphoma Metastatic Mali... Metastatic Mela... Metastatic Rena... Recurrent Bladd... Recurrent Class... Recurrent Head ... Recurrent Lymph... Recurrent Malig... Recurrent Renal... Stage III Bladd... Stage III Lymph... Stage III Non-S... Stage III Renal... Stage III Skin ... Stage IIIA Non-... Stage IIIA Skin... Stage IIIB Non-... Stage IIIB Skin... Stage IIIC Skin... Stage IV Bladde... Stage IV Lympho... Stage IV Non-Sm... Stage IV Renal ... Stage IV Skin M... Stage IVA Bladd... Stage IVB Bladd... Unresectable He... Unresectable So...	Enzyme Inhibito... Laboratory Biom... Nivolumab Pembrolizumab	18 Years -	Rutgers, The State University of New Jersey
Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners	NCT03112668	Malignant Femal... Malignant Hepat... Partner Stage III Breas... Stage III Cervi... Stage III Color... Stage III Lung ... Stage III Prost... Stage III Skin ... Stage III Uteri... Stage IIIA Brea... Stage IIIA Cerv... Stage IIIA Colo... Stage IIIA Lung... Stage IIIA Skin... Stage IIIA Uter... Stage IIIB Brea... Stage IIIB Cerv... Stage IIIB Colo... Stage IIIB Lung... Stage IIIB Skin... Stage IIIB Uter... Stage IIIC Brea... Stage IIIC Colo... Stage IIIC Skin... Stage IIIC Uter... Stage IV Breast... Stage IV Cervic... Stage IV Colore... Stage IV Lung C... Stage IV Prosta... Stage IV Skin M... Stage IV Uterin... Stage IVA Cervi... Stage IVA Color... Stage IVA Uteri... Stage IVB Cervi... Stage IVB Color... Stage IVB Uteri...	Cognitive Behav... Quality-of-Life... Questionnaire A... Survey Administ...	18 Years -	Rutgers, The State University of New Jersey
A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases	NCT02941744	Stage IIIC Skin... Stage IV Skin M...	nivolumab ipilimumab	18 Years -	Universitair Ziekenhuis Brussel
MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery	NCT02320305	Stage IIA Skin ... Stage IIB Skin ... Stage IIC Skin ... Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M...	MART-1 Antigen TLR4 Agonist GL... Laboratory Biom...	18 Years -	Mayo Clinic
Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma	NCT00026221	Recurrent Melan... Stage IV Skin M...	Recombinant Int... Bevacizumab	18 Years -	National Cancer Institute (NCI)
Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy	NCT01789827	Stage IV Skin M...	Laboratory Biom... Radionuclide Im... Technetium Tc 9...	18 Years -	Mayo Clinic
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma	NCT00976573	Melanoma (Skin)	bevacizumab carboplatin everolimus paclitaxel	18 Years -	Alliance for Clinical Trials in Oncology
MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery	NCT02320305	Stage IIA Skin ... Stage IIB Skin ... Stage IIC Skin ... Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M...	MART-1 Antigen TLR4 Agonist GL... Laboratory Biom...	18 Years -	Mayo Clinic
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer	NCT02318771	Head and Neck S... Metastatic Rena... Recurrent Head ... Recurrent Lung ... Recurrent Renal... Recurrent Skin ... Stage III Renal... Stage IV Lung C... Stage IV Skin M...	Radiation Thera... MK-3475	18 Years -	Thomas Jefferson University
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma	NCT00019682	Recurrent Melan... Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M...	Aldesleukin gp100 Antigen Montanide ISA 5... Quality-of-Life... Questionnaire A... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma	NCT00976573	Melanoma (Skin)	bevacizumab carboplatin everolimus paclitaxel	18 Years -	Alliance for Clinical Trials in Oncology

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: